These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 37345979

  • 1. Dual inhibition of STAT3 and STAT5 may overcome imatinib resistance in chronic myeloid leukemia.
    Yin L, Xu J, Wu W, Niu M, Li Z, Zhu F, Xu K.
    Hematology; 2023 Dec; 28(1):2224625. PubMed ID: 37345979
    [Abstract] [Full Text] [Related]

  • 2. JKST6, a novel multikinase modulator of the BCR-ABL1/STAT5 signaling pathway that potentiates direct BCR-ABL1 inhibition and overcomes imatinib resistance in chronic myelogenous leukemia.
    Aranda-Tavío H, Recio C, Martín-Acosta P, Guerra-Rodríguez M, Brito-Casillas Y, Blanco R, Junco V, León J, Montero JC, Gandullo-Sánchez L, McNaughton-Smith G, Zapata JM, Pandiella A, Amesty A, Estévez-Braun A, Fernández-Pérez L, Guerra B.
    Biomed Pharmacother; 2021 Dec; 144():112330. PubMed ID: 34673425
    [Abstract] [Full Text] [Related]

  • 3. Cryptotanshinone suppresses key onco-proliferative and drug-resistant pathways of chronic myeloid leukemia by targeting STAT5 and STAT3 phosphorylation.
    Dong B, Liang Z, Chen Z, Li B, Zheng L, Yang J, Zhou H, Qu L.
    Sci China Life Sci; 2018 Sep; 61(9):999-1009. PubMed ID: 30054832
    [Abstract] [Full Text] [Related]

  • 4. Silencing of suppressor of cytokine signaling-3 due to methylation results in phosphorylation of STAT3 in imatinib resistant BCR-ABL positive chronic myeloid leukemia cells.
    Al-Jamal HA, Jusoh SA, Yong AC, Asan JM, Hassan R, Johan MF.
    Asian Pac J Cancer Prev; 2014 Sep; 15(11):4555-61. PubMed ID: 24969884
    [Abstract] [Full Text] [Related]

  • 5. Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia.
    Gleixner KV, Schneeweiss M, Eisenwort G, Berger D, Herrmann H, Blatt K, Greiner G, Byrgazov K, Hoermann G, Konopleva M, Waliul I, Cumaraswamy AA, Gunning PT, Maeda H, Moriggl R, Deininger M, Lion T, Andreeff M, Valent P.
    Haematologica; 2017 Sep; 102(9):1519-1529. PubMed ID: 28596283
    [Abstract] [Full Text] [Related]

  • 6. A novel tubulin polymerization inhibitor, MPT0B206, downregulates Bcr-Abl expression and induces apoptosis in imatinib-sensitive and imatinib-resistant CML cells.
    Chen CW, Lee YL, Liou JP, Liu YH, Liu CW, Chen TY, Huang HM.
    Apoptosis; 2016 Sep; 21(9):1008-18. PubMed ID: 27344662
    [Abstract] [Full Text] [Related]

  • 7. Characterization of imatinib-resistant K562 cell line displaying resistance mechanisms.
    Hekmatshoar Y, Ozkan T, Altinok Gunes B, Bozkurt S, Karadag A, Karabay AZ, Sunguroglu A.
    Cell Mol Biol (Noisy-le-grand); 2018 May 15; 64(6):23-30. PubMed ID: 29808796
    [Abstract] [Full Text] [Related]

  • 8. Persistent STAT5-mediated ROS production and involvement of aberrant p53 apoptotic signaling in the resistance of chronic myeloid leukemia to imatinib.
    Cheng Y, Hao Y, Zhang A, Hu C, Jiang X, Wu Q, Xu X.
    Int J Mol Med; 2018 Jan 15; 41(1):455-463. PubMed ID: 29115375
    [Abstract] [Full Text] [Related]

  • 9. CM363, a novel naphthoquinone derivative which acts as multikinase modulator and overcomes imatinib resistance in chronic myelogenous leukemia.
    Guerra B, Martín-Rodríguez P, Díaz-Chico JC, McNaughton-Smith G, Jiménez-Alonso S, Hueso-Falcón I, Montero JC, Blanco R, León J, Rodríguez-González G, Estévez-Braun A, Pandiella A, Díaz-Chico BN, Fernández-Pérez L.
    Oncotarget; 2017 May 02; 8(18):29679-29698. PubMed ID: 27557509
    [Abstract] [Full Text] [Related]

  • 10. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
    Ferreira AF, Moura LG, Tojal I, Ambrósio L, Pinto-Simões B, Hamerschlak N, Calin GA, Ivan C, Covas DT, Kashima S, Castro FA.
    Blood Cells Mol Dis; 2014 May 02; 53(1-2):47-55. PubMed ID: 24629639
    [Abstract] [Full Text] [Related]

  • 11. Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML).
    Lu T, Cao J, Zou F, Li X, Wang A, Wang W, Liang H, Liu Q, Hu C, Chen C, Hu Z, Wang W, Li L, Ge J, Shen Y, Ren T, Liu J, Xia R, Liu Q.
    Eur J Pharmacol; 2021 Apr 15; 897():173944. PubMed ID: 33581133
    [Abstract] [Full Text] [Related]

  • 12. Ketoconazole Reverses Imatinib Resistance in Human Chronic Myelogenous Leukemia K562 Cells.
    Prado-Carrillo O, Arenas-Ramírez A, Llaguno-Munive M, Jurado R, Pérez-Rojas J, Cervera-Ceballos E, Garcia-Lopez P.
    Int J Mol Sci; 2022 Jul 13; 23(14):. PubMed ID: 35887063
    [Abstract] [Full Text] [Related]

  • 13. Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia.
    Eiring AM, Page BDG, Kraft IL, Mason CC, Vellore NA, Resetca D, Zabriskie MS, Zhang TY, Khorashad JS, Engar AJ, Reynolds KR, Anderson DJ, Senina A, Pomicter AD, Arpin CC, Ahmad S, Heaton WL, Tantravahi SK, Todic A, Moriggl R, Wilson DJ, Baron R, O'Hare T, Gunning PT, Deininger MW.
    Leukemia; 2015 Mar 13; 29(3):586-597. PubMed ID: 25134459
    [Abstract] [Full Text] [Related]

  • 14. Emodin Inhibits Resistance to Imatinib by Downregulation of Bcr-Abl and STAT5 and Allosteric Inhibition in Chronic Myeloid Leukemia Cells.
    Wang XY, Sun GB, Wang YJ, Yan F.
    Biol Pharm Bull; 2020 Mar 13; 43(10):1526-1533. PubMed ID: 32999163
    [Abstract] [Full Text] [Related]

  • 15. Cryptotanshinone acts synergistically with imatinib to induce apoptosis of human chronic myeloid leukemia cells.
    Ge Y, Yang B, Xu X, Dai Q, Chen Z, Cheng R.
    Leuk Lymphoma; 2015 Mar 13; 56(3):730-8. PubMed ID: 24884318
    [Abstract] [Full Text] [Related]

  • 16. Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms.
    Lan X, Zhao C, Chen X, Zhang P, Zang D, Wu J, Chen J, Long H, Yang L, Huang H, Carter BZ, Wang X, Shi X, Liu J.
    J Hematol Oncol; 2016 Nov 25; 9(1):129. PubMed ID: 27884201
    [Abstract] [Full Text] [Related]

  • 17. Bone marrow-derived mesenchymal stromal cells promote resistance to tyrosine kinase inhibitors in chronic myeloid leukemia via the IL-7/JAK1/STAT5 pathway.
    Zhang X, Tu H, Yang Y, Jiang X, Hu X, Luo Q, Li J.
    J Biol Chem; 2019 Aug 09; 294(32):12167-12179. PubMed ID: 31235520
    [Abstract] [Full Text] [Related]

  • 18. Inhibition of STAT3-interacting protein 1 (STATIP1) promotes STAT3 transcriptional up-regulation and imatinib mesylate resistance in the chronic myeloid leukemia.
    Mencalha AL, Corrêa S, Salles D, Du Rocher B, Santiago MF, Abdelhay E.
    BMC Cancer; 2014 Nov 23; 14():866. PubMed ID: 25417721
    [Abstract] [Full Text] [Related]

  • 19. Cytotoxic effect of 6-Shogaol in Imatinib sensitive and resistant K562 cells.
    Ozkan T, Hekmatshoar Y, Pamuk H, Ozcan M, Yaman G, Yagiz GC, Akdemir C, Sunguroglu A.
    Mol Biol Rep; 2021 Feb 23; 48(2):1625-1631. PubMed ID: 33515349
    [Abstract] [Full Text] [Related]

  • 20. Curcumin derivative C817 inhibits proliferation of imatinib-resistant chronic myeloid leukemia cells with wild-type or mutant Bcr-Abl in vitro.
    Wu LX, Wu Y, Chen RJ, Liu Y, Huang LS, Lou LG, Zheng ZH, Chen YZ, Xu JH.
    Acta Pharmacol Sin; 2014 Mar 23; 35(3):401-9. PubMed ID: 24487968
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.